Market Price

53.91 

-0.95 -1.7%

as of Sep 13 '19

52 Week Range:

29.01 58.93


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

Anika Therapeutics, Inc., together with its subsidiaries, provides orthopedic medicines for patients with degenerative orthopedic diseases and traumatic conditions in the United States and internationally. The company develops, manufactures, and commercializes therapeutic products based on its proprietary hyaluronic acid (HA) technology. Its orthobiologics products comprise ORTHOVISC, ORTHOVISC mini, MONOVISC, and CINGAL for the treatment of osteoarthritis of the knee; HYALOFAST, a biodegradable support for human bone marrow mesenchymal stem cells used for cartilage regeneration and as an adjunct for microfracture surgery; HYALONECT, a resorbable knitted fabric mesh; HYALOSS MATRIX, HYAFF fibers used to mix blood/bone grafts to form a paste for bone regeneration; and HYALOGLIDE, an ACP gel used in tenolysis treatment. The company's dermal products include wound care products that comprise HYALOMATRIX and HYALOFILL for the treatment of complex wounds, such as burns and ulcers, and for use in connection with the regeneration of skin; and ELEVESS, an aesthetic dermatology product. Its surgical products comprise HYALOBARRIER, a post-operative adhesion barrier for use in the abdomino-pelvic area; MEROGEL, a woven fleece nasal packing; and MEROGEL INJECTABLE, a viscous hydrogel. The company also offers ophthalmic products, including injectable HA products that are used as viscoelastic agents in ophthalmic surgical procedures, such as cataract extraction and intraocular lens implantation; and veterinary products, which include HYVISC, an injectable HA product for the treatment of joint dysfunction in horses. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18
Equity (BVPS) 5.34
6.12
6.32
6.81
7.86
8.97
11.43
13.28
14.67
17.24
17.96
growth rate 14.6% 3.3% 7.8% 15.4% 14.1% 27.4% 16.2% 10.5% 17.5% 4.2%
Earnings BIT 4.73
5.51
7.34
13.79
19.53
32.48
61.45
48.83
50.61
45.73
27.95
growth rate 16.5% 33.2% 87.9% 41.6% 66.3% 89.2% -20.5% 3.6% -9.6% -38.9%
Avg.PE 9.60
23.92
21.10
15.92
12.12
27.47
16.27
22.20
21.48
24.67
26.13
growth rate 149.2% -11.8% -24.6% -23.9% 126.7% -40.8% 36.5% -3.2% 14.9% 5.9%
ROA 4.14
3.26
3.32
6.47
8.55
13.80
21.89
14.31
13.68
12.17
6.67
growth rate -21.3% 1.8% 94.9% 32.2% 61.4% 58.6% -34.6% -4.4% -11.0% -45.2%
ROE 6.27
5.16
5.16
9.41
11.54
16.83
24.43
15.82
15.01
13.09
7.10
growth rate -17.7% 0.0% 82.4% 22.6% 45.8% 45.2% -35.2% -5.1% -12.8% -45.8%
ROIC 6.10
4.30
4.57
8.30
10.47
16.83
24.43
15.82
15.01
13.09
7.10
growth rate -29.5% 6.3% 81.6% 26.1% 60.7% 45.2% -35.2% -5.1% -12.8% -45.8%
Cur. Ratio 6.18
3.01
2.91
4.41
5.35
10.19
23.27
10.21
19.37
15.78
18.32
growth rate -51.3% -3.3% 51.6% 21.3% 90.5% 128.4% -56.1% 89.7% -18.5% 16.1%
Quick Ratio 5.38
2.19
2.22
3.65
4.53
8.84
20.77
9.27
17.32
13.85
15.93
growth rate -59.3% 1.4% 64.4% 24.1% 95.1% 135.0% -55.4% 86.8% -20.0% 15.0%
Leverage 1.58
1.59
1.51
1.40
1.30
1.15
1.09
1.12
1.08
1.07
1.06
growth rate 0.6% -5.0% -7.3% -7.1% -11.5% -5.2% 2.8% -3.6% -0.9% -0.9%
Balance Sheet Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18
Acct.Receivable 5.40
11.80
14.80
19.23
23.49
19.40
17.15
21.65
27.60
23.83
20.78
growth rate 118.5% 25.4% 29.9% 22.2% -17.4% -11.6% 26.2% 27.5% -13.7% -12.8%
Acct.Payable 10.07
9.98
9.10
1.20
8.30
2.30
6.75
3.14
growth rate -0.9% -8.8% -86.8% 591.3% -72.3% 193.0% -53.4%
Cur.Assets 55.80
49.80
56.30
64.14
77.38
94.59
137.84
176.43
170.44
206.33
202.94
growth rate -10.8% 13.1% 13.9% 20.7% 22.2% 45.7% 28.0% -3.4% 21.1% -1.6%
Total Assets 95.80
129.40
128.90
132.84
142.07
156.04
192.81
235.75
240.25
282.62
278.99
growth rate 35.1% -0.4% 3.1% 6.9% 9.8% 23.6% 22.3% 1.9% 17.6% -1.3%
Cash 43.20
24.40
28.20
35.78
44.07
63.33
100.16
110.71
104.26
133.26
89.04
growth rate -43.5% 15.6% 26.9% 23.2% 43.7% 58.1% 10.5% -5.8% 27.8% -33.2%
Inventory 5.50
8.50
8.90
7.30
8.28
11.00
12.41
14.94
15.98
22.04
21.30
growth rate 54.6% 4.7% -18.0% 13.4% 32.8% 12.8% 20.4% 7.0% 37.9% -3.3%
Cur.Liabilities 9.00
16.50
19.40
14.54
14.45
9.28
5.97
17.28
8.80
13.07
11.29
growth rate 83.3% 17.6% -25.1% -0.6% -35.8% -35.7% 189.3% -49.1% 48.6% -13.7%
Liabilities 35.10
47.30
43.70
38.08
33.14
20.41
14.71
24.90
17.47
19.13
15.38
growth rate 34.8% -7.6% -12.9% -13.0% -38.4% -27.9% 69.3% -29.8% 9.5% -19.6%
LT Debt 14.40
12.80
11.20
9.60
8.00
0.00
growth rate -11.1% -12.5% -14.3% -16.7% -100.0%
Equity 60.80
82.10
85.20
94.76
108.93
135.63
178.10
210.85
222.77
263.49
263.61
growth rate 35.0% 3.8% 11.2% 14.9% 24.5% 31.3% 18.4% 5.7% 18.3% 0.1%
Common Shares 11.00
12.00
14.00
14.00
14.00
15.00
15.00
15.00
15.00
15.00
15.00
growth rate 9.1% 16.7% 0.0% 0.0% 7.1% 0.0% 0.0% 0.0% 0.0% 0.0%
Cash Flow Statement Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18
Capital Expenditures 16.20
4.00
2.80
1.40
1.51
0.44
1.55
9.23
14.01
8.98
4.66
growth rate -75.3% -30.0% -50.0% 7.5% -70.7% 252.2% 494.0% 51.9% -35.9% -48.2%
Cash Dividends 0.00 0.00 0.00 0.00 0.00
growth rate
Cash From OA 3.40
3.10
7.90
10.17
10.55
25.17
39.98
39.91
24.45
40.81
34.92
growth rate -8.8% 154.8% 28.8% 3.7% 138.6% 58.9% -0.2% -38.7% 66.9% -14.4%
FCF per Share -1.12
-0.07
0.37
0.34
0.63
1.48
2.08
2.37
0.88
2.08
1.67
growth rate 0.0% 100.0% -8.1% 85.3% 134.9% 40.5% 13.9% -62.9% 136.4% -19.7%
Sale Purchase of Stock 0.16
0.39
3.05
2.06
1.07
1.01
0.31
growth rate 143.1% 685.1% -32.7% -47.7% -6.2% -68.8%
FCF -13.00
-1.00
5.00
9.00
9.00
25.00
38.00
30.00
10.00
32.00
30.00
growth rate 0.0% 100.0% 80.0% 0.0% 177.8% 52.0% -21.1% -66.7% 220.0% -6.3%
Income Statement Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18
Sales 35.80
40.10
55.60
64.78
71.36
75.08
105.60
93.00
103.38
113.42
105.56
growth rate 12.0% 38.7% 16.5% 10.2% 5.2% 40.6% -11.9% 11.2% 9.7% -6.9%
Op.Income 4.20
5.60
7.50
8.47
11.76
20.58
61.45
48.83
50.61
45.73
27.95
growth rate 33.3% 33.9% 12.9% 38.9% 75.0% 198.7% -20.5% 3.6% -9.6% -38.9%
IBT 4.70
5.50
7.30
13.79
19.53
32.48
61.51
48.25
50.87
46.20
23.21
growth rate 17.0% 32.7% 88.8% 41.7% 66.3% 89.4% -21.5% 5.4% -9.2% -49.8%
Net Income 3.60
3.70
4.30
8.47
11.76
20.58
38.32
30.76
32.55
31.82
18.72
growth rate 2.8% 16.2% 96.9% 38.9% 75.0% 86.2% -19.7% 5.8% -2.3% -41.2%
EPS 0.32
0.32
0.32
0.62
0.82
1.39
2.51
2.01
2.15
2.11
1.27
growth rate 0.0% 0.0% 93.8% 32.3% 69.5% 80.6% -19.9% 7.0% -1.9% -39.8%
Gross Profit 22.60
26.50
31.70
38.00
42.37
52.32
84.67
71.95
79.35
86.06
74.28
growth rate 17.3% 19.6% 19.9% 11.5% 23.5% 61.8% -15.0% 10.3% 8.5% -13.7%
R&D 7.40
8.20
6.90
6.17
5.39
7.06
8.14
8.29
10.73
18.79
18.19
growth rate 10.8% -15.9% -10.6% -12.7% 31.0% 15.4% 1.8% 29.5% 75.1% -3.2%

Quarterly Statements

Item Name Jun '18 Sep '18 Dec '18 Mar '19 Jun '19
Earnings BIT 11.25
8.57
9.76
5.76
11.92
growth rate -23.8% 13.9% -41.0% 106.8%
Balance Sheet Jun '18 Sep '18 Dec '18 Mar '19 Jun '19
Acct.Receivable 23.39
20.77
20.78
18.27
23.07
growth rate -11.2% 0.0% -12.1% 26.3%
Acct.Payable 5.07
2.46
3.14
3.57
2.29
growth rate -51.5% 27.7% 13.6% -36.0%
Cur.Assets 190.99
195.59
202.94
209.70
189.92
growth rate 2.4% 3.8% 3.3% -9.4%
Total Assets 265.41
269.26
278.99
306.66
287.36
growth rate 1.5% 3.6% 9.9% -6.3%
Cash 126.05
81.83
89.04
95.51
69.41
growth rate -35.1% 8.8% 7.3% -27.3%
Inventory 24.06
23.83
21.30
22.62
22.99
growth rate -1.0% -10.6% 6.2% 1.6%
Cur.Liabilities 12.53
9.31
11.29
11.60
10.39
growth rate -25.8% 21.3% 2.8% -10.5%
Liabilities 18.81
14.00
15.38
37.59
36.42
growth rate -25.6% 9.9% 144.4% -3.1%
LT Debt 22.23
21.97
growth rate -1.2%
Equity 246.60
255.27
263.61
269.07
250.95
growth rate 3.5% 3.3% 2.1% -6.7%
Common Shares 0.15
0.14
0.14
0.14
0.14
growth rate -2.7% 0.0% 0.0% -2.8%
Cash Flow Statement Jun '18 Sep '18 Dec '18 Mar '19 Jun '19
Capital Expenditures 0.74
1.21
0.16
1.03
1.10
growth rate 63.5% -86.5% 531.9% 6.9%
Cash Dividends
growth rate
Cash From OA 4.47
10.84
10.01
8.46
5.47
growth rate 142.5% -7.7% -15.5% -35.4%
Sale Purchase of Stock 2.37
growth rate
FCF 3.73
9.63
9.85
7.43
4.37
growth rate 158.2% 2.3% -24.6% -41.2%
Income Statement Jun '18 Sep '18 Dec '18 Mar '19 Jun '19
Sales 30.55
26.79
26.96
24.72
30.42
growth rate -12.3% 0.6% -8.3% 23.0%
Op.Income 11.25
8.57
9.76
5.76
11.92
growth rate -23.8% 13.9% -41.0% 106.8%
IBT 11.54
9.10
10.31
5.98
12.45
growth rate -21.2% 13.4% -42.0% 108.2%
Net Income 10.09
7.60
7.72
4.51
9.44
growth rate -24.7% 1.6% -41.6% 109.3%
EPS
growth rate
Gross Profit 22.40
18.51
19.96
17.41
23.58
growth rate -17.4% 7.8% -12.7% 35.4%
R&D 4.73
4.23
4.06
4.26
4.17
growth rate -10.6% -4.0% 4.8% -2.2%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

D (44.67)

YOY Growth Grade:

D (45.39)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

PE and EPS

Historical Current Forward
PE 19.19 26.37 33.24
EPS / Growth 6.9% 2.04 10.0%

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 11.8%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 6.9% 9.6% 9.6%
Future PE 13.84 23.85 23.85
Future EPS 3.99 5.09 5.09
Value Price
MOS %
13.65
-74.7%
30.03
-44.3%
30.03
-44.3%
MOS Price 6.83 15.01 15.01
IRT 14.88 13.08 13.08

Graham Number:

NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.